BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
Ram Laxman brings executive leadership experience from 10x Genomics, Illumina, and Pacific Biosciences to expand BioSkryb’s international footprint
GelSight Unveils New GelSight Mobile Shock Protected Edition
Ruggedized to withstand harsh environments, the newest addition to GelSight’s product line up brings even more resilient 3D surface analysis tools to the field and the production line
6K Energy Announces the Creation of the “6K for 6K Scholars” with Lane College
The first scholarship winner, Amashia Mabone, is to be honored on November 10th at the 6K Energy office in Jackson, TN
BioSkryb Genomics to Present New Single-Cell Multiomic Data at ASHG 2023
BioSkryb will participate in two CoLab Sessions on single-cell whole genome sequencing and four poster presentations with new pancreatic and breast cancer data
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress
Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101
Niron Magnetics’ Clean Earth Magnet Named to TIME’s List of the Best Inventions of 2023
Recognition as one of 200 world-changing innovations validates the need for Niron Magnetics’ rare earth-free magnet technology as demand for permanent magnets rises
AM Batteries Nabs Industry Veterans from Tesla, Celgard to Mass Produce Low CO2 Footprint Li-ion EV Batteries
AM Batteries appoints former president of Celgard, Lie Shi, as CEO and Maxwell, GE and Tesla Veteran, Hieu Duong, as Chief Manufacturing Officer
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research
ImmunoScape’s platform accelerates the discovery of efficacious TCR-based therapeutics for solid tumors
InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
InterVenn’s Serum Glycoproteome Profiling resulted in Sensitivities of 90.9% for Advanced Adenoma without High Grade Dysplasia, 85.7% for Advanced Adenoma with High Grade Dysplasia and 89.8% for all stages of Colorectal Cancer in discovery study.
Codetta Bio Appoints Life Sciences Industry Leader Jacques Corriveau as CEO
Corriveau brings 25 years of commercial and operational leadership experience in life sciences, biopharma, and diagnostics from Ultivue, AstraZeneca, Roche and NanoString